S-1/A: Scientific Industries Faces Liquidity Challenges Amidst Bioprocessing Growth Strategy, Registers Shares for Resale

Sentiment:

Registration Statement Amendment 18 July 2025 12:03 PM

📋All filings for Scientific Industries INC

Scientific Industries, Inc. (SCND) filed an S-1/A registration statement for the resale of 3.1 million shares by existing stockholders, highlighting ongoing financial losses, a going concern risk, and a strategic pivot towards its Bioprocessing Systems segment despite current revenue declines.

Delay expectedBioprocessing products have taken 'much longer to develop than previously anticipated'.New bioprocessing products will be subject to beta testing and adoption by end users, which 'could result in design and/or production changes which could further delay development time'.

Capital raiseThe company completed a private placement transaction on April 18, 2025, raising $1,550,000 through the sale of common stock and warrants.The company explicitly states that it 'may be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements, product line divestitures, or other sources' to fund its product development and commercialization programs and continue as a going concern.

Worse than expectedThe company explicitly states that its operating cash flow, cash on hand, and recent financing efforts are 'not sufficient to fund our cash requirements over the next twelve months,' leading to a 'going concern' uncertainty.Despite cost-cutting, the company continues to incur significant net losses ($1.78 million in Q1 2025, $6.45 million in FY 2024) and has a large accumulated deficit ($35.7 million), indicating persistent financial challenges.Overall net revenues decreased in both the recent quarter and the last fiscal year, driven by declines in the established Benchtop Laboratory Equipment segment, which is supposed to be stable and profitable.

Summary

The S-1/A filing is for the resale of up to 3,100,000 shares of common stock by selling stockholders, including 1,050,000 shares from an April 18, 2025 private placement, 500,000 shares from pre-funded warrants, and 1,550,000 shares from common warrants.
The company will not receive proceeds from the sale of shares by selling stockholders, but will receive proceeds from the exercise of warrants.
Scientific Industries operates in two segments: Benchtop Laboratory Equipment (stable and profitable) and Bioprocessing Systems (growth opportunity, but currently incurring losses).
The company reported a net loss of $1,778,500 for the three months ended March 31, 2025, an improvement from a $2,051,600 loss in the prior year period, primarily due to cost-cutting in Bioprocessing Systems.
Net revenues for the three months ended March 31, 2025, decreased by 3.1% to $2,406,500, driven by a $182,600 decrease in Bioprocessing Systems revenues, partially offset by a $105,600 increase in Benchtop Laboratory Equipment.
For the year ended December 31, 2024, the net loss was $6,445,400, a reduction from $9,086,500 in 2023, attributed to decreased expenses from operational cost reductions in Bioprocessing Systems.
Annual net revenues for 2024 decreased by 3.6% to $10,712,600, with Bioprocessing Systems revenues increasing by $323,700 (due to the new DOTS MPS product) and Benchtop Laboratory Equipment revenues decreasing by $722,600 (due to reduced Torbal division sales, especially VIVID pill counters, and overall market softness for Genie products).
The company had an accumulated deficit of $35,709,000 as of March 31, 2025, and $33,930,500 as of December 31, 2024.
Cash and cash equivalents decreased by $208,200 to $587,900 as of December 31, 2024.
The company's liquidity is deemed insufficient to fund cash requirements over the next twelve months, raising a going concern risk.
A private placement on April 18, 2025, raised $1,550,000 through the sale of common stock and warrants.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture with ongoing losses, insufficient liquidity, and a stated going concern risk. While there's a strategic focus on a high-growth bioprocessing segment, its commercial success is uncertain and product development has faced delays. The primary purpose of the filing is for resale by existing shareholders, not a direct capital raise for the company's operations, further emphasizing the financial strain.

Positives

The Benchtop Laboratory Equipment segment is stable and profitable, providing a foundational revenue stream.
Cost-cutting initiatives in the Bioprocessing Systems Operations segment led to a reduced net loss for the three months ended March 31, 2025, and the year ended December 31, 2024.
The Bioprocessing Systems segment, despite current losses, is identified as having greater growth opportunities within the large and expanding synthetic biology market.
Introduction of new products like the DOTS MPS product contributed to increased revenues in the Bioprocessing Systems segment for the year ended December 31, 2024.
Gross profit percentage for the three months ended March 31, 2025, slightly increased to 42.2% due to higher gross margin in Bioprocessing Systems Operations.

Negatives

The company has a history of significant net losses, including $1,778,500 for Q1 2025 and $6,445,400 for FY 2024, and expects to incur future operating losses.
An accumulated deficit of $35,709,000 as of March 31, 2025, indicates substantial past losses.
Current liquidity, including existing cash, operating cash flow, and recent financing, is considered insufficient to fund cash requirements for the next twelve months, raising a going concern risk.
Overall net revenues decreased by 3.1% for Q1 2025 and 3.6% for FY 2024.
The Benchtop Laboratory Equipment segment experienced a revenue decrease of $722,600 in 2024, primarily due to reduced sales of Torbal division products (VIVID pill counters affected by new DIR fees) and overall market softness for Genie products.
Gross profit percentage for FY 2024 decreased to 44.2% from 45.9% in 2023, primarily due to increased cost of materials, labor, and fixed overhead for the Benchtop Laboratory Equipment Operations.
The company is a small participant in highly competitive industries, facing significantly larger competitors with greater resources.
Heavy dependence on a single product, the Vortex-Genie 2 Mixer, which accounted for approximately 34% of total net revenues in Q1 2025 and 33% and 32% in FY 2024 and 2023, respectively, and lacks patent protection.
The company relies heavily on distributors for its Benchtop Laboratory Equipment, and sales of new products are dependent on distributor decisions and catalog inclusion, which can take 24 to 36 months.
Bioprocessing products are complex and have taken longer to develop than anticipated, with potential for further delays due to beta testing and design changes.

Risks

Limited financial resources and the potential inability to raise additional funding when needed, which could force delays, reductions, or elimination of product development and commercialization programs.
Future funding requirements are uncertain and depend on various factors, including product candidate scope, timing of collaborations, number of future candidates, and costs of sales, marketing, manufacturing, and intellectual property protection.
Raising additional capital may dilute existing stockholders' ownership interests, impose restrictive covenants through debt financing, or require relinquishing valuable rights to technologies or product candidates.
A history of net losses and the expectation of continued operating losses for the foreseeable future, with no assurance of achieving or sustaining profitability.
Risk of failing to maintain proper and effective internal control over financial reporting, which could impair the ability to produce accurate and timely financial statements and harm stock value.
Limited public market for common stock and thin trading, leading to high volatility and potentially impairing the value of shares and the company's ability to raise capital or enter strategic partnerships.
Commercial success of bioprocessing products depends on attaining significant market acceptance, which is uncertain in a relatively new and rapidly innovating market.
Inability to obtain and maintain sufficient patent and other intellectual property protection for new bioprocessing products, allowing competitors to develop similar products.
Challenges in protecting trademarks and trade names, which could impede brand recognition and competitive effectiveness.
Loss of key management personnel could seriously harm the ability to implement business strategy effectively.
Reliance on highly skilled personnel and intense competition for qualified employees in the biopharmaceutical sector.
Heavy dependence on international operations, particularly the Bioprocessing Systems Operations in Germany, which poses inherent risks in internal controls and is subject to differing laws and regulations.
Inability to successfully manage any experienced growth, placing strain on management and administrative, operational, and financial resources.
Growth strategy assumptions regarding the bioprocessing market (e.g., total addressable market and serviceable addressable market estimates) may prove incorrect, adversely impacting the business.
Dependence on major customers, with two customers accounting for 10% or more of total revenue for Q1 2025, and the top three Benchtop customers accounting for 24% and 18% of segment sales in 2024 and 2023, respectively.
Significant portion of revenues derived from a single Benchtop Laboratory Equipment product (Vortex-Genie 2 Mixer), increasing vulnerability to market shifts or competition for that product.
Small market participant status in highly competitive industries, facing larger competitors with greater financial, production, and marketing resources.
Inability to develop and effectively market new products, particularly for the Benchtop Laboratory Equipment segment, to reduce dependence on the Vortex-Genie 2 Mixer.
Exposure to foreign exchange rate risk (transactional and translational, particularly USD vs. Euro) due to international operations.
Vulnerability to general economic, political, and social factors, including budgetary constraints affecting customer funding (e.g., government grants) and the impact of a high U.S. dollar value on overseas sales.
Increased material and transportation costs, which could negatively affect future gross margins if not passed on to customers.
Heavy dependence on outside suppliers for components, with reliance on a few suppliers for critical components, leading to long lead times and risks related to foreign production and tariffs.
Limited patent protection for principal Benchtop Laboratory Equipment products, making them vulnerable to competition from similar products.
No anticipation of declaring or paying cash dividends for the foreseeable future, limiting stockholder returns to stock appreciation.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future as expenses related to the growth and expansion of its Bioprocessing Systems operations are anticipated to exceed revenues. The ability to conduct additional research and development and commercialization efforts is dependent on future funding availability. The company's management has developed a strategic plan to secure additional capital resources, which may include capital from management and significant shareholders, third-party equity and/or debt financing, and exploring asset sales, but cannot provide assurances of success.

Management Comments

Management believes there are greater growth opportunities in the Bioprocessing Systems segment, as part of a large and expanding synthetic biology market sector worldwide.
The acquisition of Aquila in April 2021 was an initial step towards expanding the Bioprocessing Systems segment and developing new products and technologies.
Management has concentrated on establishing a commercialization strategy for bioprocessing products, with the initial product launch of the DOTS software platform in September 2022, followed by the Multi-Parameter Sensor in November 2023.
Management believes that substantial capital investment will be needed in the bioprocessing sector for the foreseeable future to achieve product development and commercialization success.
Management has developed a strategic plan to secure additional capital resources, including potential capital from management and significant shareholders, third-party equity/debt financing, and asset sales, to continue as a going concern.

Industry Context

Scientific Industries operates in two distinct but related industries: the mature and highly competitive benchtop laboratory equipment market, where it is a small participant with a dominant product (Vortex-Genie 2 Mixer), and the emerging, rapidly innovating bioprocessing products industry, specifically the laboratory-scale sector. In the bioprocessing sector, the company is in a start-up phase, competing against significantly larger companies. The bioprocessing market is estimated to be large and expanding, particularly within synthetic biology, offering significant growth potential if the company can successfully commercialize its new products and gain market acceptance. However, the industry is characterized by rapid innovation and uncertainty, requiring substantial R&D investment and effective intellectual property protection.

Comparison to Industry Standards

The company's Benchtop Laboratory Equipment segment, with annual sales of $9,022,800 in 2024, is significantly smaller than many competitors in the highly competitive and mature laboratory equipment industry.
The Bioprocessing Systems operations are in a start-up phase within an industry dominated by several significantly larger companies, indicating a substantial competitive disadvantage in terms of financial, production, and marketing resources.
The company's reliance on a single product, the Vortex-Genie 2 Mixer, for a substantial portion of its Benchtop Laboratory Equipment sales (36% of segment sales in 2024) is a concentration risk not typical of diversified industry leaders.
The estimated worldwide bioprocess development technologies total available market (TAM) of approximately $26 billion and a serviceable addressable market (SAM) for the company's bioprocessing products of $2.1 billion suggest a significant market opportunity, but the company's current revenue from this segment is minimal in comparison, indicating a long path to capturing meaningful market share against established players like Thermo Fisher Scientific, Danaher, Sartorius, or Merck KGaA, which have extensive product portfolios and global distribution networks.
The decline in Torbal division sales, particularly VIVID pill counters, due to new regulations related to pharmacy direct and indirect remuneration (DIR) fees, highlights vulnerability to regulatory changes, a common challenge across healthcare-related industries, but particularly impactful for smaller players with less diversified product lines.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	NA	Michael Blechman	April 2024	Election to the Board of Directors
Director	NA	John Nicols	March 4, 2024	Election to the Board of Directors

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The board of directors is divided into three classes with staggered three-year terms, with only one class elected annually.	NA	Intended to deter hostile takeovers and promote board stability by making it harder to replace the entire board quickly.
Voting Rights	Stockholders do not have cumulative voting rights, meaning a majority of outstanding shares can elect all directors.	NA	Concentrates voting power in majority shareholders, potentially limiting minority shareholder influence in director elections.
Special Meeting Call	Only the board of directors, president, secretary, or holders of 66 2/3% in interest of voting stockholders may call a special meeting.	NA	Restricts the ability of a significant minority of shareholders to call special meetings, potentially delaying shareholder action.
Related Party Transaction Approval	A 'Subject Transaction' with a 'Related Party' requires 80% voting stock approval, unless 2/3 of the Board approves AND stockholders receive at least $6.00 per share.	NA	Provides a high threshold for certain transactions involving significant shareholders, potentially protecting against unfavorable deals but also deterring beneficial ones if the price threshold is not met.
Anti-Takeover Provisions (Delaware Law)	Subject to Section 203 of the DGCL, which prohibits certain business combinations with 'interested stockholders' (15% or more ownership) for three years, with specific exceptions.	NA	Deters hostile takeovers by making it difficult for an interested stockholder to complete a business combination without board approval or a supermajority vote, potentially reducing share price fluctuations from takeover rumors.
Director Liability Limitation	Amended certificate of incorporation limits or eliminates director liability for monetary damages for breach of fiduciary duties, except for specific breaches (e.g., duty of loyalty, bad faith, unlawful payments, improper personal benefit).	NA	Aims to attract and retain qualified directors by reducing personal financial risk, but does not eliminate liability for certain severe misconduct or under federal securities laws.
Indemnification	Bylaws provide for indemnification of directors and executive officers to the fullest extent permitted by Delaware law, and the company enters into separate indemnification agreements.	NA	Further protects directors and officers from liabilities, including advancing expenses, which is intended to attract and retain qualified personnel but may shift legal costs to the company.

Related Party Transactions

Certain selling stockholders have had material relationships with the company within the past three years, as disclosed in the prospectus under 'Relationships with Certain Selling Stockholders'. These include Michael Blechman (director since April 2024), John A. Moore (Chairman since January 2020, director since January 2019), and John Nicols (Director since March 2024).

Stakeholder Impact

**Shareholders**: Face significant dilution risk from future capital raises and potential loss of investment due to the company's history of losses and going concern risk. Returns are limited to stock appreciation as no dividends are anticipated. The resale of shares by selling stockholders could put downward pressure on the stock price.
**Employees**: Subject to potential workforce reductions, as seen in the Bioprocessing Systems Operations, due to cost-cutting initiatives. The company's ability to retain and hire highly skilled personnel is critical for future success.
**Customers**: May experience delays in new bioprocessing product development and potential impacts on product availability or pricing due to supply chain issues and increased costs. Dependence on major customers for Benchtop Laboratory Equipment sales creates risk if those relationships deteriorate.
**Suppliers**: The company's heavy dependence on a few outside suppliers for critical components, with long lead times and foreign production risks, could impact supplier relationships and payment terms if financial difficulties persist.
**Creditors**: Face increased risk due to the company's stated insufficient liquidity and going concern uncertainty, which could affect the company's ability to meet its financial obligations.

Next Steps

Continue to invest substantial capital into bioprocessing product development and commercialization programs.
Seek additional funding through public or private equity offerings, debt financings, collaborations, licensing arrangements, or product line divestitures.
Further upgrade systems, implement additional financial and management controls, reporting systems, and procedures, and hire additional accounting and finance staff to comply with reporting requirements.
Continue efforts to develop and effectively market new Benchtop Laboratory Equipment products to increase revenues and reduce dependence on the Vortex-Genie 2 Mixer.
Successfully develop, produce, and market new bioprocessing products, including completing beta testing and addressing potential design/production changes.

Key Dates

Date	Description
1954-07-02	Scientific Industries, Inc. incorporated in Delaware.
2018-12-14	Last date cash dividends were paid on common stock.
2019-06-30	End of fiscal year when the company began committing substantial resources to Bioprocessing Systems operations.
2019-01-23	John A. Moore elected to the Board of Directors.
2020-01-29	John A. Moore became Chairman of the Board of Directors.
2021-04-29	Acquisition of Aquila biolabs GmbH.
2022-09-01	Initial product launch of the DOTS software platform.
2023-03-29	Date of Mazars USA LLP's report on consolidated financial statements for the year ended December 31, 2023.
2023-12-31	Fiscal year end for which net loss was $9,086,500 and net revenues were $11,111,500.
2023-12-31	Cash and cash equivalents were $796,100.
2024-03-04	John Nicols became a Director of the Company.
2024-03-31	Date of Forvis Mazars, LLP's report on consolidated financial statements for the year ended December 31, 2024.
2024-04-01	April 2024: Michael Blechman became a director.
2024-12-31	Fiscal year end for which net loss was $6,445,400 and net revenues were $10,712,600.
2024-12-31	Cash and cash equivalents were $587,900.
2025-03-31	End of the three months for which net loss was $1,778,500 and net revenues were $2,406,500.
2025-03-31	Accumulated deficit was $35,709,000.
2025-04-18	Date of the private placement transaction where selling stockholders acquired common stock and warrants.
2025-06-20	Last reported sale price of common stock was $0.648 per share.
2025-06-20	Number of common stock shares outstanding was 11,553,599.
2025-07-01	Date the Registration Statement on Form S-1 was filed with the SEC.
2025-07-18	Date of the S-1/A filing and associated legal opinions/consents.

Recommendation

sell

Keywords

Bioprocessing Systems, Laboratory Equipment, SEC Filing, S-1/A, Private Placement, Warrants, Common Stock, Liquidity Risk, Going Concern, Net Loss, Revenue Decline, Market Acceptance, Intellectual Property, Supply Chain, SCND, Scientific Industries

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.